Genetic clamping of renin gene expression induces hypertension and elevation of intrarenal Ang II levels of graded severity in Cyp1a1-Ren2 transgenic rats

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 7, Issue 2, 2006, Pages 74-86

  Mitchell, Kenneth D ^a   Bagatell, Stuart J ^a   Miller, Chad S ^a   Mouton, Cynthia R ^a   Seth, Dale M ^a   Mullins, John J ^b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Angiotensin II; Arterial blood pressure; Kidney; Peptide hormones; Radioimmunoassay; Renal haemodynamics; Renin Angiotensin system

Indexed keywords

3 INDOLEMETHANOL; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; AROMATIC HYDROCARBON; CANDESARTAN; CYTOCHROME P450 1A1; KIDNEY RENIN;

ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; GENE EXPRESSION REGULATION; GLOMERULUS FILTRATION; HORMONE BLOOD LEVEL; KIDNEY BLOOD FLOW; MALE; MALIGNANT HYPERTENSION; NONHUMAN; PHENOTYPE; PLASMA RENIN ACTIVITY; RADIOIMMUNOASSAY; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRANSGENIC ANIMAL; URINARY EXCRETION; WEIGHT REDUCTION;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; GENE EXPRESSION; HYPERTENSION; HYPERTENSION, MALIGNANT; INDOLES; KIDNEY; MALE; MICE; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 33748655839     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2006.013     Document Type: Article

References (42)

1. Byrom FB. The nature of malignancy in hypertensive disease. Evidence from the retina of the rat. Lancet 1963; 1:516-20.
2. Gavras H, Brunner HR, Laragh JH et al. Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res 1975;36(2):300-09.
3. Ploth DW. Angiotensin-dependent renal mechanisms in two-kidney one-clip renal vascular hypertension. Am J Physiol Renal Fluid Electrolyte Physiol 1983;245: F131-F141.
4. Mullins JJ, Ganten D. Transgenic animals: new approaches to hypertension research. J Hypertens 1990;8(7):35S-37S.
5. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990;344:541-4.
6. Bohlender J, Fukamizu A, Lippoldt A et al. High human renin hypertension in transgenic rats. Hypertension 1997;29:428-34.
7. Luft FC, Mervaala E, Muller DN et al. Hypertension-induced end-organ damage: A new transgenic approach to an old problem. Hypertension 1999;33:212-18.
8. Lavoie JL, Lake-Bruse KD, Sigmund CD. Increased blood pressure in transgenic mice expressing both human renin and angiotensinogen in the renal proximal tubule. Am J Physiol Renal Physiol 2004;286:F965-F971.
9. Kantachuvesiri S, Fleming S, Peters J et al. Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease. J Biol Chem 2001;276:36727-33.
10. Campbell SJ, CarlotLi F, Hall PA, Clark AJ, Wolf CR. Regulation of the CYP1A1 promoter in transgenic mice: an exquisitely sensitive on-off system for cell specific gene regulation. J Cell Sci 1996; 109:2619-25.
11. Forrester LM, Henderson CJ, Glancey MJ et al. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J 1992;281:359-68.
12. Smith JD, Wong E, Ginsberg M. Cytochrome P450 1A1 promoter as a genetic switch for the regulatable and physiological expression of a plasma protein in transgenic mice. Proc Natl Acad Sci USA 1995;92:1926-30.
13. Gelboin HV. Benzo[alphalpyrene metabolism, activation and carcinogenesis: role and regulation of mixed-function oxidases and related enzymes. Physiol Rev 1980; 60:1107-66.
14. Jellinck PH, Forkert PG, Riddick DS, Okey AB, Michnovicz JJ, Bradlow HL. Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. Biochem Pharmacol 1993;45:1129-36.
15. Loub WD, Wattenberg LW, Davis DW Aryl hydrocarbon hydroxylase induction in rat tissues by naturally occurring indoles of cruciferous plants. J Natl Cancer Inst 1975; 54:985-8.
16. Pelkonen O, Nebert DW Metabolism of polycyclic aromatic hydrocarbons: etiologic role in carcinogenesis. Pharmacol Rev 1982;34:189-222.
17. Fujii-Kuriyama Y, Masatsuga E, Junsei M, Matsushita N, Sogawa K. Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene. Pharmacogenetics 1995; 5:149-53.
18. Von Thun AM, Vari RC, El-Dahr SS, Navar LG. Augmentation of intrarenal Angiotensin II levels by chronic Angiotensin II infusion. Am J Physiol Renal Fluid Electrolyte Physiol 1994;266:F120-F128.
19. Zou L, Hymel A, Imig JD, Navar LG. Renal accumulation of circulating Angiotensin II in Angiotensin II-infused rats. Hjpertension 1996;27:658-62.
20. Zou L, Imig JD, Von Thun AM, Hymel A, Ono H, Navar LG. Receptor-mediated intrarenal Ang II augmentation in Ang 11-infused hypertensive rats. Hypertension 1996;28:669-77.
21. 1 receptor. Am J Hypertens 1998;11:570-8.
22. Howard LL, Patterson ME, Mullins JJ, Mitchell KD. Salt-sensitive hypertension develops after transient induction of Aug II-dependent hypertension in Cyp1a1-Ren2 transgenic rats. Am J Physiol Renal Physiol 2005;288:F810-F815.
23. Patterson ME, Mouton CR, Mullins JJ, Mitchell KD. Interactive effects of superoxide anion and nitric oxide on blood pressure and renal hemodynamics in transgenic rats with inducible malignant hypertension. Am J Physiol Renal Physiol 2005;289:F754-F759.
24. Guan S, Fox J, Mitchell KD, Navar LG: Angiotensin and Angiotensin converting enzyme tissue levels in two-kidney, one clip hypertensive rats. Hypertension 1992;20:763-7.
25. Mitchell KD, Mullins JJ. Ang II dependence of tubuloglomerular feedback responsiveness in hypertensive ren-2 transgenic rats. Am J Physiol Renal Fluid Electrolyte Pbysiol 1995;268:F821-F828.
26. Mitchell KD, Jacinto SM, Mullins JJ. Proximal tubular fluid, kidney, and plasma levels of Angiotensin II in hypertensive ren-2 transgenic rats. Am J Physiol Renal Physiol 1997;273: F246-F253.
27. Fox J, Guan S, Hymel AA, Navar LG. Dietary Na and ACE inhibition effects on renal tissue Angiotensin I and II and ACE activity in rats. Am J Physiol Renal Physiol 1992; 262:F902-F909.
28. Braam B, Mitchell KD, Fox J, Navaf LG. Proximal tubular secretion of Angiotensin II in rats. Am J Physiol Renal Physiol 1993;264:F891-F898.
29. Navar LG, Lewis L, Hymel A, Braam B, Mitchell KD. Tubular fluid concentrations and kidney contents of Angiotensins I and II in anesthetized rats. J Am Soc Nephrol 1994;5:1153-8.
30. Imig JD, Navar LG. Measurement of renal tubular Angiotensin II. In: WAng D (ed.): Methods in Molecular Medicine, vol. 51: Angiotensin Protocols. Totowa, NJ: Humana Press Inc.; 2000,pp. 427-34.
31. Whitworth CE, Fleming S, Cumming AD, Morton JJ et al. Spontaneous development of malignant phase hypertension in transgenic ren-2 rats. Kidney Int 1994;46:1528-32.
32. Mann SJ, Atlas SA. Hypertensive Emergencies. In: Laragh JH, Brenner BM (eds.): Hypertension: Pathophysiology, Diagnosis, and Maintenance. 2nd ed. New York, NY Raven; 1995, pp. 3009-22.
33. Whitworth CE, Fleming S, Kotelevtsev Y et al. A genetic model of malignant phase hypertension in rats. Kidney Int 1995;47:529-35.
34. Kantachuvesiri S, Haley CS, Fleming S et al. Genetic mapping of modifier loci affecting malignant hypertension in TGRmRen2 rats. Kidney Int 1999; 56:414-20.
35. Mitchell KD, Mullins JJ. Enhanced tubuloglomerular feedback in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am J Physiol Renal Physiol 2005;289;F1210-F1216.
36. Blantz RC, Konnen KS, Tucker BJ. Angiotensin II effects upon the glomerular ultrafiltration coefficient of the rat. J Clin Invest 1976;57:419-34.
37. Baylis C, Brenner BM. Modulation by prostaglandin synthesis inhibitors of the action of exogenous Angiotensin II on glomerular ultrafiltration in the rat. Circ Res 1978; 43:889-98.
38. Navar LG, Inscho EW, Majid DSA, Imig JD, Harrison-Bernard LM, Mitchell KD. Paracrine regulation of the renal microcirculation. Physiol Rev 1996;76:425-36.
39. Mitchell KD, Navar LG. Intrarenal actions of angiotensin II in the pathogenesis of experimental hypertension. in: Laragh JH, Brenner BM (eds.): Hypertension: Pathophysiology, Diagnosis, and Maintenance. 2nd ed. New York, NY: Raven; 1995, pp. 1437-50.
40. 1 receptor mediated augmentation of intrarenal angiotensinogen in Angiotensin II-dependent hypertension. Hypertension 2004;43:1126-32.
41. 1 receptor in adult rat kidney using a monoclonal antibody. Am J Physiol Renal Physiol 1997;273:F170-F177.
42. Graciano ML, Mouton C, Patterson ME, Mullins JJ, Mitchell KD. Renal vascular and tubulointerstitial inflammation and proliferation in Cyp1a1-Ren2 transgenic rats with malignant hypertension. FASEB J 2005;19:A548.